ClinicalTrials.gg
CompletedNCT00799708Updated Mar 16, 2016Results posted

A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)

A Phase 1 interventional study of Comparator: placebo and Comparator: Estrace in Postmenopause, sponsored by Merck Sharp & Dohme LLC. Completed. Open to female participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
40 Years and older
Sex
Female
01

Study summary

This study will develop a model for the assessment of successful activation/engagement of estrogen receptor beta using salivary biomarkers.

02

Conditions studied

  • Postmenopause

Keywords

  • Biomarkers of estrogen receptor beta activation
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is healthy, woman at least 40 years of age with onset of menopause within 10 years of screening
  • Subject has a normal mammogram at screening
  • Subject has had a normal Pap-smear within 3 years of screening. Subjects who have not had a Pap-smear in the last 3 years will have the option to have the test at screening
  • Subject agrees to avoid medications that cause dry mouth or otherwise affect saliva flow
  • Subject is willing to avoid strenuous exercise during the study
  • Subject is willing to avoid use of mouthwash or salt water rinses during the study
  • Subject is willing to avoid use of teeth whitening products
  • Subject is willing to avoid eating and/or drinking grapefruit products
  • Subject is willing to limit alcohol consumption to 2 drinks a day
  • Subject is willing to limit caffeine consumption to 3 cups of coffee (or equivalent) per day
  • Subject is a non-smoker

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of multiple and/or severe allergies to drugs or food
  • Subject has a cold or viral infection within 2 weeks of Visit 2
  • Subject is taking antibiotics within 2 weeks of Visit 2
  • Subject needs dental work or procedures during the study
  • Subject has used any estrogen or progesterone preparation or product containing phytoestrogens within 3 months of screening
  • Subject is unable to discontinue anti-coagulants
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Comparator: placebo

  • Active comparator
    2

    Estrace 0.5 mg

    Drug: Comparator: Estrace

  • Active comparator
    3

    Estrace 2 mg

    Drug: Comparator: Estrace

Interventions

  • DrugComparator: placebo

    placebo capsule once daily for 7 days.

  • Estrace 0.5 mg or 2 mg tablets once daily for 7 days.

    Also known as: Estrace

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7

    Subset of genes on the log ratio intensity scale from a microarray platform - signature was pre-specified from an internally conducted study in knock-out mice treated with estrogens- quantified as a ratio of up regulated versus down regulated genes

    Time frame: Baseline and Day 7

Secondary outcomes

  1. Change From Baseline in Minor Gland Salivary Flow Rate After Treatment With 2 mg Estradiol vs Placebo at Day 7.

    Change from baseline in unstimulated labial gland saliva flow rate at Day 7

    Time frame: Baseline and Day 7

07

Results

Posted Jul 29, 2010

Participant flow

This was a randomized, double-blind, placebo-controlled parallel group study in healthy postmenopausal women. Enrollment occurred from May 2008 through October 2008 across two US Phase I clinical research centers.

Participant flow — Overall Study
Milestone17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlacebo
Started10611
Completed9611
Not completed100
Withdrew: Non-compliance100

Outcome measures

PrimaryChange From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7

Subset of genes on the log ratio intensity scale from a microarray platform - signature was pre-specified from an internally conducted study in knock-out mice treated with estrogens- quantified as a ratio of up regulated versus down regulated genes

Time frame:
Baseline and Day 7
Reported as:
Least squares mean · Fold change
Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 7
Fold change17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlacebo
Change From Baseline in Estrogen Receptor Beta (ERbeta) -Specific Gene Signature After Treatment With 2 mg, 0.5 mg, or no Estradiol (Placebo) at Day 70.028 ± 0.036-0.011 ± 0.0480.080 ± 0.039
Statistical analysis
  • 17β-estradiol 2.0 Milligrams vs Placebo · ANOVA · p = 0.345
  • 17β-estradiol 0.5 Milligrams vs Placebo · ANOVA · p = 0.166
SecondaryChange From Baseline in Minor Gland Salivary Flow Rate After Treatment With 2 mg Estradiol vs Placebo at Day 7.

Change from baseline in unstimulated labial gland saliva flow rate at Day 7

Time frame:
Baseline and Day 7
Reported as:
Least squares mean · μL/min
Change From Baseline in Minor Gland Salivary Flow Rate After Treatment With 2 mg Estradiol vs Placebo at Day 7.
μL/min17β-estradiol 2.0 MilligramsPlacebo
Change From Baseline in Minor Gland Salivary Flow Rate After Treatment With 2 mg Estradiol vs Placebo at Day 7.-0.26 (-0.65 to 0.13)-0.64 (-1.00 to -0.28)
Statistical analysis
  • 17β-estradiol 2.0 Milligrams vs Placebo · ANCOVA · p = 0.120 · Mean difference (final values): 0.38 · 90% CI -0.16 to 0.92

Adverse events

Collected over AEs were collected from the time the subject signed the consent form until 14 days following the last dose of study medication.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
17β-estradiol 2.0 Milligrams—0/10 (0%)8/10 (80%)
17β-estradiol 0.5 Milligrams—0/6 (0%)4/6 (66.7%)
Placebo—0/11 (0%)7/11 (63.6%)
Most frequent other events
Showing 10 of 28
Most frequent other events
Event17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlacebo
HeadacheNervous system disorders3/101/62/11
Lip PainGastrointestinal disorders2/101/63/11
Lip SwellingGastrointestinal disorders0/100/62/11
PalpitationsCardiac disorders0/101/60/11
Chest DiscomfortGeneral disorders0/101/60/11
Tongue BitingNervous system disorders0/101/60/11
DiarrhoeaGastrointestinal disorders1/100/60/11
Stomach DiscomfortGastrointestinal disorders1/100/60/11
Joint InjuryInjury, poisoning and procedural complications1/100/60/11
Procedural Site ReactionInjury, poisoning and procedural complications1/100/60/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlaceboTotal
Mean54.3 ± 5.053.8 ± 4.454.4 ± 4.854.2 ± 4.6
Sex: Female, Male
Sex: Female, Male(Participants)17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlaceboTotal
Female1061127
Male0000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)17β-estradiol 2.0 Milligrams17β-estradiol 0.5 MilligramsPlaceboTotal
Mean29.1 ± 6.128.7 ± 3.229.2 ± 4.829.0 ± 4.9
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2008
First posted
Dec 1, 2008
Start
May 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Jul 29, 2010
Last update
Mar 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00799708
Responsible party
Sponsor
First posted
Dec 1, 2008
Start date
May 2008
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Jul 29, 2010
Last update
Mar 16, 2016

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion